Roger Schibli, PhD, developed and tested a new treatment using Terbium-161, capable of more accurately killing individual neuroendocrine cancer cells and eliminating ultra-small cancer lesions that can cause disease recurrence.

Home » Roger Schibli, PhD, developed and tested a new treatment using Terbium-161, capable of more accurately killing individual neuroendocrine cancer cells and eliminating ultra-small cancer lesions that can cause disease recurrence.